中国北京与美国新罕布什尔州汉诺威 — 12月24日— 一家临床阶段的兽用肿瘤治疗公司Jenga Biosciences, Inc. （Jenga Biosciences）今日宣布其已与专注于动物保健医药的生物技术公司——北京伟杰信生物科技有限公司（伟杰信生物）签署了一项独家许可协议。根据协议，Jenga Biosciences将获得一款免疫检查点抑制剂，即犬特异性抗PD-1单克隆抗体的开发和商业化权益。

根据协议条款，Jenga Biosciences将获得该疗法在中国以外所有国家的独家开发、生产和商业化权利。该协议约定，未来根据达成开发、注册和商业里程碑的情况，Jenga Biosciences潜在将向伟杰信生物支付总额高达1亿美元的款项。

在患犬中开展的探索性临床研究取得积极结果

此次授权的抗PD-1候选药物已完成一项涵盖24只患犬的探索性临床研究。结果表明，该候选药物在多种肿瘤类型中均表现出良好的安全性和积极的疗效，其中包括在头颈部肿瘤中展现早期信号。作为一款完全犬源化的单克隆抗体，该疗法专为犬类免疫系统设计，为兽医肿瘤学提供了一款“best-in-class”的免疫治疗方案。

打造领先的犬类免疫疗法组合

此项协议标志着Jenga Biosciences的产品管线迎来了第二个候选产品，其显著拓展了该公司的肿瘤学项目。此次授权的抗PD-1候选药物（即JEN-102）有望解锁联合治疗策略，并与该公司核心的IL-12免疫疗法项目JEN-101形成互补。JEN-101主要针对口腔黑色素瘤及其他实体瘤。

尽管现有手术、放疗和化疗等治疗手段可能有效，但仍存在局限性。免疫疗法提供了一种差异化的作用机制，有望实现更持久的应答，从而满足兽医癌症护理领域一项重大未被满足的需求。

对犬类癌症治疗的影响

癌症仍然是犬类的主要致死原因，每四只犬中有一只在一生中会确诊癌症。

“抗PD-1疗法已经彻底改变了人类肿瘤学的治疗格局，从根本上重塑了多种癌症患者的生存期和生活质量，” Jenga Biosciences科学顾问委员会负责人、兽医学博士、美国兽医内科学院（肿瘤学）认证专家Heather Wilson-Robles博士表示。其还表示，“将这类强大的免疫疗法带给犬类患者，是兽医肿瘤学领域一次意义重大的进步。”

“我们的目标是将世界一流的科学成果带给兽医，并为癌症患犬拓展治疗选择，” Jenga Biosciences执行董事长兼首席执行官Julia Stephanus表示。她还表示，“此次合作通过推进一款经过临床验证的用于患犬的抗PD-1疗法，使我们离这一目标更近了一步。”

“伟杰信生物致力于利用尖端前沿技术，推动高质量、创新性的生物免疫疗法进步，” 伟杰信生物创始人兼董事长罗昊澍博士表示。罗昊澍博士还表示，“我们与Jenga Biosciences优势互补、合作共赢——Jenga在兽医肿瘤学领域的领先优势和伟杰信生物在生物制药创新方面的综合专长联合互补。我们很高兴看到这款抗PD-1疗法朝着全球可及的目标迈进，为癌症患犬带来更长、更健康生活的新希望。”

关于Jenga Biosciences

Jenga Biosciences是一家临床阶段的兽用生物治疗公司，致力于开发用于犬类癌症的新一代免疫疗法。公司专注于将经过验证的人类肿瘤学作用机制转化为安全、有效且可及的宠物疗法，正在打造一个领先的免疫疗法组合，以解决兽医学领域中最严峻且未被满足的需求。请访问www.jengabio.com了解更多信息。

关于伟杰信生物(VJTBio)

伟杰信生物是一家总部位于中国北京的动物保健公司，致力于创新动保药的发现、开发、生产和商业化。公司专注于用于经济类动物繁殖、疫病防控及伴侣动物慢性病治疗的重组蛋白和抗体的研发与生产。请访问https://global.vjtbio.com了解更多信息。

Jenga Biosciences Licenses Canine Anti-PD-1 Immunotherapy from VJTBio to Advance Next-Generation Cancer Treatments for Dogs

Under the terms of the agreement, Jenga Biosciences receives exclusive rights to develop, manufacture, and commercialize the therapy in all countries outside of China. The agreement provides for potential future payments to VJTBio of up to $100 million, contingent upon the achievement of development, regulatory, and commercial milestones.

Promising Pilot Study Results in Dogs

The licensed anti-PD-1 candidate has completed a pilot clinical study in twenty-four dogs, demonstrating good safety and promising efficacy across multiple tumor types, including early signals in head and neck cancers. As a fully caninized monoclonal antibody, the therapy is designed specifically for the canine immune system, providing a best-in-class immunotherapy approach for veterinary oncology.

Building a Leading Portfolio of Canine Immunotherapies

This agreement marks the second product candidate in Jenga’s pipeline and a notable expansion of its oncology program. JEN-102, the anti-PD-1 candidate, is expected to unlock combination strategies and complement JEN-101, the company’s anchored IL-12 immunotherapy program targeting oral melanoma and other solid tumors.

While current treatments such as surgery, radiation, and chemotherapy can be effective, they are not without limitations. Immunotherapy offers a differentiated mechanism of action with the potential for more durable responses, addressing a critical unmet need in veterinary cancer care.

Impact on Treating Canine Cancer

Cancer remains the leading cause of death in dogs, and 1 in 4 dogs will be diagnosed with cancer in their lifetime.

“Anti-PD-1 therapies have transformed what is possible in human oncology, fundamentally reshaping survival and quality of life across a wide range of cancers,” said Dr. Heather Wilson-Robles, DVM, DACVIM (Oncology), leader of the Scientific Advisory Board for Jenga Biosciences. “Bringing this powerful class of immunotherapies to canine patients represents a meaningful advance for veterinary oncology.”

“Our goal is to bring world-class science to veterinarians and expand the treatment options for dogs with cancer,” said Julia Stephanus, Executive Chair and CEO of Jenga Biosciences. “This collaboration moves us closer to that goal by advancing a clinically validated anti-PD-1 therapy for canine patients.”

“At VJTBio, we are committed to advancing high-quality, innovative biologic immunotherapies powered by cutting-edge technologies,” said Dr. Haoshu Luo, Founder and Chair of VJTBio. “Our collaboration with Jenga Biosciences brings together complementary strengths—Jenga’s leadership in veterinary oncology and our integrated expertise in biologics innovation. We are excited to see this anti-PD-1 therapy progress toward worldwide availability, giving dogs with cancer new hope for longer, healthier lives.”

About Jenga Biosciences

Jenga Biosciences is a clinical-stage veterinary biotherapeutics company developing next-generation immunotherapies for canine cancer. With a focus on translating proven human oncology mechanisms into safe, effective, and accessible treatments for pets, Jenga is building a leading portfolio of immunotherapies to address the most serious unmet needs in veterinary medicine. Learn more at www.jengabio.com.

About VJTBio

VJTBio is an animal healthcare company based in Beijing, China, dedicated to the discovery, development, production, and commercialization of innovative veterinary medicines. The company specializes in recombinant proteins and antibodies for veterinary use in livestock reproduction, infectious diseases, and chronic diseases in companion animals. Learn more at https://global.vjtbio.com.